Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1997 Dec;6(5-6):323–326. doi: 10.1080/09629359791451

Pulmonary hypertension in infants with congenital heart defects: are leukotrienes involved?

A Serraf 1, J-P Gascard 2, J Bruniaux 1, C Labat 2, C Planche 1, C Brink 2,✉
PMCID: PMC2365871  PMID: 18472866

Abstract

The circulating levels of leukotriene E4 in infants with congenital heart defects, increased pulmonary blood flow and pulmonary arterial hypertension, were determined and compared with infants with decreased pulmonary blood flow (Tetralogy of Fallot). There was no correlation (r=0.38) between the pulmonary arterial pressure (56 ± 4 mmHg) and the leukotriene E4 levels (1.37 ± 0.67 ng/ml blood) measured in peripheral blood samples from the hypertensive group prior to surgery. There was considerable variation in the detectable leukotriene E4 levels in blood samples from different patients. The levels detected in the blood samples between the two groups of patients was similar. These data suggest that neither the surgical repair during cardiopulmonary bypass nor the pulmonary hypertension appeared to modify the leukotriene E4 blood levels in the small number of patients studied.

Full Text

The Full Text of this article is available as a PDF (149.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berkowitz B. A., Zabko-Potapovich B., Valocik R., Gleason J. G. Effects of the leukotrienes on the vasculature and blood pressure of different species. J Pharmacol Exp Ther. 1984 Apr;229(1):105–112. [PubMed] [Google Scholar]
  2. Bernard G. R., Korley V., Chee P., Swindell B., Ford-Hutchinson A. W., Tagari P. Persistent generation of peptido leukotrienes in patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1991 Aug;144(2):263–267. doi: 10.1164/ajrccm/144.2.263. [DOI] [PubMed] [Google Scholar]
  3. Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., Loyd J. E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):70–75. doi: 10.1056/NEJM199207093270202. [DOI] [PubMed] [Google Scholar]
  4. Cook A. J., Yuksel B., Sampson A. P., Greenough A., Price J. F. Cysteinyl leukotriene involvement in chronic lung disease in premature infants. Eur Respir J. 1996 Sep;9(9):1907–1912. doi: 10.1183/09031936.96.09091907. [DOI] [PubMed] [Google Scholar]
  5. Gorenne I., Labat C., Gascard J. P., Norel X., Müller-Peddinghaus R., Mohrs K. H., Taylor W. A., Gardiner P. J., Brink C. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther. 1994 Feb;268(2):868–872. [PubMed] [Google Scholar]
  6. Heavey D. J., Soberman R. J., Lewis R. A., Spur B., Austen K. F. Critical considerations in the development of an assay for sulfidopeptide leukotrienes in plasma. Prostaglandins. 1987 May;33(5):693–708. doi: 10.1016/0090-6980(87)90035-9. [DOI] [PubMed] [Google Scholar]
  7. Kumlin M., Dahlén S. E. Characteristics of formation and further metabolism of leukotrienes in the chopped human lung. Biochim Biophys Acta. 1990 May 22;1044(2):201–210. doi: 10.1016/0005-2760(90)90304-g. [DOI] [PubMed] [Google Scholar]
  8. Labat C., Ortiz J. L., Norel X., Gorenne I., Verley J., Abram T. S., Cuthbert N. J., Tudhope S. R., Norman P., Gardiner P. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther. 1992 Nov;263(2):800–805. [PubMed] [Google Scholar]
  9. Lee T. H., Crea A. E., Gant V., Spur B. W., Marron B. E., Nicolaou K. C., Reardon E., Brezinski M., Serhan C. N. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis. 1990 Jun;141(6):1453–1458. doi: 10.1164/ajrccm/141.6.1453. [DOI] [PubMed] [Google Scholar]
  10. Manning P. J., Rokach J., Malo J. L., Ethier D., Cartier A., Girard Y., Charleson S., O'Byrne P. M. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990 Aug;86(2):211–220. doi: 10.1016/s0091-6749(05)80068-5. [DOI] [PubMed] [Google Scholar]
  11. Sampson A. P., Green C. P., Spencer D. A., Piper P. J., Price J. F. Leukotrienes in the blood and urine of children with acute asthma. Ann N Y Acad Sci. 1991;629:437–439. doi: 10.1111/j.1749-6632.1991.tb38011.x. [DOI] [PubMed] [Google Scholar]
  12. Schreiber M. D., Heymann M. A., Soifer S. J. The differential effects of leukotriene C4 and D4 on the pulmonary and systemic circulations in newborn lambs. Pediatr Res. 1987 Feb;21(2):176–182. doi: 10.1203/00006450-198702000-00013. [DOI] [PubMed] [Google Scholar]
  13. Smedegård G., Hedqvist P., Dahlén S. E., Revenäs B., Hammarström S., Samuelsson B. Leukotriene C4 affects pulmonary and cardiovascular dynamics in monkey. Nature. 1982 Jan 28;295(5847):327–329. doi: 10.1038/295327a0. [DOI] [PubMed] [Google Scholar]
  14. Stenmark K. R., James S. L., Voelkel N. F., Toews W. H., Reeves J. T., Murphy R. C. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med. 1983 Jul 14;309(2):77–80. doi: 10.1056/NEJM198307143090204. [DOI] [PubMed] [Google Scholar]
  15. Westcott J. Y., McDonnell T. J., Voelkel N. F. Alveolar transfer and metabolism of eicosanoids in the rat. Am Rev Respir Dis. 1989 Jan;139(1):80–87. doi: 10.1164/ajrccm/139.1.80. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES